Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clesrovimab in healthy pre-term and full-term infants
NCT04767373Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing Clesrovimab 105 mg with Placebo (2 arms). Primary endpoints: Respiratory Syncytial Virus-Associated Medically Attended Lower Respiratory Infection at 150 days, Solicited Injection-Site Adverse Events at 5 days and 6 more. Started Apr 2021; status: completed.
02
Drugs
clesrovimab-cfor
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04767373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767373.